1. Home
  2. PRAX vs G Comparison

PRAX vs G Comparison

Compare PRAX & G Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Praxis Precision Medicines Inc.

PRAX

Praxis Precision Medicines Inc.

N/A

Current Price

$302.17

Market Cap

9.6B

Sector

Health Care

ML Signal

N/A

Logo Genpact Limited

G

Genpact Limited

N/A

Current Price

$38.27

Market Cap

7.2B

ML Signal

N/A

Company Overview

Basic Information
Metric
PRAX
G
Founded
2015
1997
Country
United States
Bermuda
Employees
N/A
140000
Industry
Biotechnology: Pharmaceutical Preparations
Professional Services
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
9.6B
7.2B
IPO Year
2020
2007

Fundamental Metrics

Financial Performance
Metric
PRAX
G
Price
$302.17
$38.27
Analyst Decision
Strong Buy
Buy
Analyst Count
15
6
Target Price
$572.13
$49.50
AVG Volume (30 Days)
317.3K
1.9M
Earning Date
05-12-2026
05-07-2026
Dividend Yield
N/A
1.96%
EPS Growth
N/A
9.82
EPS
N/A
3.13
Revenue
N/A
$2,279,438,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$6,395.88
$7.26
P/E Ratio
N/A
$12.23
Revenue Growth
N/A
N/A
52 Week Low
$26.70
$34.79
52 Week High
$354.87
$51.28

Technical Indicators

Market Signals
Indicator
PRAX
G
Relative Strength Index (RSI) 46.04 45.26
Support Level $290.36 $37.58
Resistance Level $322.32 $40.44
Average True Range (ATR) 16.31 1.03
MACD -3.55 0.04
Stochastic Oscillator 28.40 29.19

Price Performance

Historical Comparison
PRAX
G

About PRAX Praxis Precision Medicines Inc.

Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. It is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company applies genetic insights to the discovery and development of therapies for neurological disorders through two proprietary platforms: Cerebrum and Solidus. It has established a diversified, multimodal CNS portfolio with four clinical-stage product candidates across movement disorders and epilepsy, which include Ulixacaltamide, Relutrigine, Vormatrigine, and Elsunersen. The firm operates in only one segment and is focused on discovering and developing therapies for CNS disorders.

About G Genpact Limited

Genpact Ltd is a provider of business process management services. Clients are industry verticals and operate in banking and financial services, insurance, capital markets, consumer product goods, life sciences, infrastructure, manufacturing and services, healthcare, and high-tech. Genpact's services include aftermarket, direct procurement, risk and compliance, human resources, IT, industrial solutions, collections, finance and accounting, and media services. Genpact's end market by revenue is India. It is a General Electric spin-off, which is still a large source of revenue for Genpact.

Share on Social Networks: